SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Charles Darwin — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharles Darwin
Date of birth1809-02-12
IdentifiersMRN HR-NI003-SYN-TD; SSN (made up) 000-03-2967
Document date1849-09-08
AuthorBernard Ashworth, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review of cyclic vomiting syndrome. [S]

History of Present Illness

Mr. Darwin returns after three months at amitriptyline 75 mg at bedtime. He has had one episode in that time, three weeks ago, after an overnight journey with little sleep. He used the sumatriptan spray and an ondansetron tablet at the first nausea and trembling, lay down in a dark room, and was well again within about four hours, without vomiting more than twice. He has had no emergency visits. The dry mouth persists, the constipation is better with more fluid and fiber, and the morning grogginess has faded. He walks most days, practices the relaxation breathing most evenings, and has accepted more invitations than in the spring. He still has some wind between episodes, which troubles him less. [S]

ElementDetail
MedicineAmitriptyline 75 mg at bedtime for three months at the target dose
EpisodesOne brief episode in three months, after overnight travel, aborted within about four hours
Side effectsDry mouth; constipation improved; grogginess gone
FunctionWorking most days; going out more

Review of Systems

SystemResultFinding
GastrointestinalPositiveWind between episodes, less troublesome; one brief episode; constipation improved
Ears, nose, mouth, and throatPositiveDry mouth
CardiovascularNegativeNo palpitations outside the prodrome; no fainting
PsychiatricNegativeMood good; worry about episodes much less; no thoughts of self-harm

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amitriptyline 25 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-14 to 1849-04-28completedS
Amitriptyline 50 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-04-28 to 1849-05-12completedS
Amitriptyline 75 mg oral tablet, one tablet at bedtimeOne tablet by mouth at bedtimeOral route1849-05-12activeS
Sumatriptan 20 mg nasal spray, one spray at the first sign of an episodeOne spray in one nostril at the start of the prodrome; may repeat once after 2 hours; no more than 2 sprays a day or 6 a weekNasal route1849-04-14activeS
Ondansetron 8 mg orally disintegrating tablet at the first sign of an episodeDissolve one tablet on the tongue at the start of the prodrome, then every 8 hours as needed during an episodeOral route1849-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1849-09-08Body height183cmS
1849-09-08Body weight72.9kgS
1849-09-08Body mass index (BMI) [Ratio]21.8kg/m2S
1849-09-08Systolic blood pressure116mm[Hg]S
1849-09-08Diastolic blood pressure72mm[Hg]S
1849-09-08Heart rate70/minS
1849-09-08Respiratory rate14/minS
1849-09-08Body temperature36.6CelS
1849-09-08Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1849-09-08Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S
1849-09-08Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Physical Exam

Vital signs recorded on 1849-09-08; see the Vital Signs section. [S]

SystemFinding
GeneralWell and relaxed; weight 72.9 kg
CardiovascularRegular rhythm at 70 per minute; blood pressure 116/72 mmHg
AbdomenSoft and non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Cyclic vomiting syndrome, moderate to severe, meeting Rome IV criteria after a normal work-up; provisional clinical diagnosisactiveprovisional R11.15S — Synthetic provisional diagnosis at the gastroenterology consultation, anchored to his documented episodic vomiting. It is clinical, with no confirmatory test, and does not confirm any historical theory.
Recurrent episodes of nausea and vomiting over more than a year, with prodromal trembling, palpitations, and dizziness, and flatulence and fatigue between episodes; cause under evaluationresolvedconfirmed R11.2S — Synthetic presenting concern at the index visit, superseded by the provisional diagnosis at the six-week visit; the episodic vomiting is documented (D).
Common cold, without a vomiting episode; resolvedresolvedconfirmed J00S — Synthetic intercurrent illness at an unscheduled visit; chosen because infection is a common trigger of cyclic vomiting and because cold medicines interact with amitriptyline. It does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Self-managementEpisode diary: number, length, and severity of episodes, prodrome, emergency visits, and missed workEvery visitCompleted todayOne episode in three months, about four hours, aborted at the prodrome; no emergency visits
ExaminationRome IV criteria and red flags (vomiting between episodes, weight loss, nocturnal pain, neurological signs, onset after 50)At diagnosis and with any change in patternCompleted todayPattern unchanged and milder; no red flags
LaboratoryBlood count, electrolytes and glucose, liver panel, lipase, urinalysis, TSH, cortisol, celiac serologyAt diagnosis between episodes; repeat only for an atypical episodeUp to dateNormal at diagnosis; no atypical episode
ImagingUpper endoscopy and small-bowel imaging (CT enterography)Once at diagnosisUp to dateNormal at diagnosis
ImagingGastric emptying studyNot routine; only between episodes when gastroparesis is suspectedNot indicatedNo symptoms of gastroparesis
Medication safetyECG with QTc on amitriptyline and ondansetron (below 450 ms in men)Baseline, at about 50 mg during titration, and at the target doseUp to dateQTc 436 ms at 75 mg three months ago; repeat only with a dose change or a new QT-prolonging medicine
Medication safetyAmitriptyline tolerability: drowsiness, dry mouth, constipation, dizziness on standing, weightEach visit on treatmentCompleted todayDry mouth persists; constipation and grogginess improved; weight 72.9 kg (up 1.5 kg since starting)
SurveyMood and thoughts of self-harm on a tricyclic (PHQ-9)Each visit on treatmentCompleted todayPHQ-9 3, with item 9 scored 0
SurveyAnxiety screen (GAD-7)At diagnosis, then every three monthsCompleted todayGAD-7 5, down from 8 at the first visit
Medication safetyAbortive plan: timing and response to sumatriptan nasal spray and ondansetron, and dose limitsEvery visitCompleted todayUsed once, at the prodrome, with relief in about four hours; within dose limits
Self-managementIndividualized emergency department protocol letterAt diagnosis; update with any change in treatmentUp to dateLetter carried; no change in treatment, so no update needed
Self-managementTriggers: sleep, meals, travel, social stress, infectionsEvery visitCompleted todayOvernight travel with short sleep triggered the one episode; a travel plan agreed
Self-managementCannabis and other substance use, and hot-bathing behavior (cannabinoid hyperemesis syndrome)At diagnosis and yearlyUp to dateNo cannabis use; recheck yearly
ExaminationComorbidities: migraine, orthostatic and autonomic symptoms, sleep disordersAt diagnosis and yearlyUp to dateNo migraine, orthostatic symptoms, or sleep disorder
Medication safetyMitochondrial supplements (coenzyme Q10, riboflavin)Conditional; consider with a partial responseNot indicatedGood response to amitriptyline
Medication safetyAlternative prophylaxis (topiramate or aprepitant)Only if amitriptyline fails or is not toleratedNot indicatedAmitriptyline effective and tolerated
Self-managementRelaxation training, meditation, or biofeedback; cognitive behavioral therapy offeredOngoingCompleted todayBreathing practice most evenings; he does not want cognitive behavioral therapy now, and the offer stays open
ExaminationWeight and hydrationEvery visitCompleted today72.9 kg; well hydrated

Goal progress:

Guideline basis: Guidelines on management of cyclic vomiting syndrome in adults by the American Neurogastroenterology and Motility Society and the Cyclic Vomiting Syndrome Association (2019); Anxiety Disorders in Adults: Screening (2023)

Follow-up: Review in three months; at one year, discuss a slow taper of amitriptyline if he stays well. [S]